Vernal Keratoconjunctivitis Pipeline Insight

DelveInsight’s, “Vernal Keratoconjunctivitis – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vernal Keratoconjunctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Vernal Keratoconjunctivitis Understanding

Vernal Keratoconjunctivitis: Overview

Vernal Keratoconjunctivitis is a severe inflammatory disease that appears in children and adolescents with seasonal recurrence. It is most often seen in boys and tends to resolve at puberty. It is a relatively rare, chronic form of ocular allergy that can cause severe visual complications. Clinically, Vernal Keratoconjunctivitis can be divided into 3 subtypes: conjunctival, limbal, and mixed presentations.


Disease severity seems milder in limbal Vernal Keratoconjunctivitis, leading some to suspect that it is the early presentation of a spectrum of disease. However, there appears to be variability in the prevalence of certain types, based on geography and atopic history, which suggests that the pathogenesis of the two types may be different. The most common symptoms are itching, photophobia, burning, and tearing. The most common signs are giant papillae, superficial keratitis, and conjunctival hyperaemia.


Differential diagnosis of Vernal Keratoconjunctivitis includes any of the chronic allergic conjunctivitis’s including seasonal allergic conjunctivitis, perennial allergic conjunctivitis, atopic keratoconjunctivitis, or giant papillary conjunctivitis, as well as chlamydial infection, especially in the early stages on the disease. Vernal Keratoconjunctivitis may be differentiated from the above disorders by hypertrophic papillae in the tarsal form of Vernal Keratoconjunctivitis or Horner Trantas dots in the limbal form, or a combination of the two, along with no involvement of the eyelids.


There is currently no defined gold-standard treatment algorithm for Vernal Keratoconjunctivitis, but there are many options available, and treatment should be tailored to the individual. Whatever treatment regimen is prescribed, it should be initiated promptly and the patient should be monitored closely for the development of any corneal complications. Therapies that are used for the treatment of Vernal Keratoconjunctivitis include:

  • Mast cell stabilizers
  • Antihistamines
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Topical corticosteroids
  • Cyclosporine
  • Tacrolimus
  • Other therapies: Corticosteroids or other immunomodulatory agents

Vernal Keratoconjunctivitis Emerging Drugs Chapters

This segment of the Vernal Keratoconjunctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vernal Keratoconjunctivitis Emerging Drugs

  • Lirentelimab (AK002): Allakos

Lirentelimab is an investigational, non-fucosylated IgG1 monoclonal antibody targeting Siglec-8. By targeting Siglec-8, an inhibitory receptor, lirentelimab blocks multiple inflammatory pathways. In clinical and preclinical studies, binding of lirentelimab to Siglec-8 induces inhibition of mast cells, apoptosis of tissue eosinophils, and depletion of blood eosinophils by antibody dependent cellular cytotoxicity (ADCC). Lirentelimab is being developed in several mast cell and eosinophil driven diseases, and has demonstrated positive clinical activity in eosinophilic gastrointestinal diseases (EGIDs), chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.

Further product details are provided in the report……..

Vernal Keratoconjunctivitis: Therapeutic Assessment

This segment of the report provides insights about the different Vernal Keratoconjunctivitis drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Vernal Keratoconjunctivitis

There are approx. 5+ key companies which are developing the therapies for Vernal Keratoconjunctivitis. The companies which have their Vernal Keratoconjunctivitis drug candidates in the early stage, i.e. phase I include, Allakos etc.

  • Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Vernal Keratoconjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • Monoclonal antibodies
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vernal Keratoconjunctivitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vernal Keratoconjunctivitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vernal Keratoconjunctivitis drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Vernal Keratoconjunctivitis R&D. The therapies under development are focused on novel approaches to treat/improve Vernal Keratoconjunctivitis.
  • July 2020: Extension study shows efficacy of cyclosporine in treatment of vernal keratoconjunctivitis.
  • An 8-month follow-up extension of the Vernal Keratoconjunctivitis Study, or VEKTIS, showed that continuous use of cyclosporine is safe and effective for the treatment of vernal keratoconjunctivitis in children and adolescents.
  • The VEKTIS study was originally a 4-month evaluation of the safety and efficacy of cyclosporine A cationic emulsion (CsA CE) 0.1% eye drops administered four times daily (high dose) or twice daily (low dose) vs. vehicle only. One hundred sixty-nine patients between the ages of 4 and 17 years were included.

Vernal Keratoconjunctivitis Report Insights

  • Vernal Keratoconjunctivitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Vernal Keratoconjunctivitis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Vernal Keratoconjunctivitis drugs?
  • How many Vernal Keratoconjunctivitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vernal Keratoconjunctivitis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vernal Keratoconjunctivitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Vernal Keratoconjunctivitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Santen SAS
  • Allakos, Inc.
  • Astellas Pharma Inc.
  • Laboratoires Thea

Key Products

  • NOVA22007
  • AK002
  • Cyclosporine
  • FK506



Executive Summary

Vernal Keratoconjunctivitis: Overview

• Causes

• Mechanism of Action

• Signs and Symptoms

• Diagnosis

• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type

• Assessment by Stage and Product Type

• Assessment by Route of Administration

• Assessment by Stage and Route of Administration

• Assessment by Molecule Type

• Assessment by Stage and Molecule Type

Vernal Keratoconjunctivitis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• Vernal Keratoconjunctivitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Vernal Keratoconjunctivitis Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis

• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

NOVA22007: Santen SAS

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase II)

• Comparative Analysis

AK002: Allakos, Inc.

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

• Comparative Analysis

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Vernal Keratoconjunctivitis Key Companies

Vernal Keratoconjunctivitis Key Products

Vernal Keratoconjunctivitis- Unmet Needs

Vernal Keratoconjunctivitis- Market Drivers and Barriers

Vernal Keratoconjunctivitis- Future Perspectives and Conclusion

Vernal Keratoconjunctivitis Analyst Views

Vernal Keratoconjunctivitis Key Companies


List of Tables

 Table 1 Total Products for Vernal Keratoconjunctivitis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List of Figures

 Figure 1 Total Products for Vernal Keratoconjunctivitis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

  • Tags:
  • Vernal Keratoconjunctivitis Pipelin...
  • Vernal Keratoconjunctivitis clinica...
  • Vernal Keratoconjunctivitis compani...
  • Vernal Keratoconjunctivitis drugs
  • Vernal Keratoconjunctivitis therapi...
  • Vernal Keratoconjunctivitis treatme...

Forward to Friend

Need A Quote